• Skylight Health Group (SLHG) has announced a non-brokered private placement for gross proceeds of up to $2 million
  • The company will issue up to 2,000 debenture units at $1,000 per unit
  • Each debenture will bear an annual interest rate of 8 per cent, paid quarterly in shares
  • The proceeds from the offering will be used for general working capital purposes
  • Skylight Health operates a U.S. multi-state primary care health network providing sub-specialty, allied health and laboratory/diagnostic testing
  • Skylight Health Group Inc. (SLHG) opened trading at $0.7369

Skylight Health Group (SLHG) has announced a non-brokered private placement for gross proceeds of up to $2 million.

The company will issue up to 2,000 debenture units at $1,000 per unit.

Each debenture will bear an annual interest rate of 8 per cent, paid quarterly in shares, and shall have a maturity date of February 15, 2025.

Each debenture shall be convertible into 1,111 common shares at C$0.90. Each debenture holder shall also receive 1,111 share purchase warrants. Each warrant entitles the holder to purchase one common share for a period 24 months.

The proceeds from the offering will be used for general working capital purposes.

The offering is expected to close on or about August 15, 2022.

Skylight Health operates a U.S. multi-state primary care health network providing sub-specialty, allied health and laboratory/diagnostic testing.

Skylight Health Group Inc. (SLHG) opened trading at $0.7369.


More From The Market Online

The 5-Minute Investor Podcast, Ep. 72: The next AI gold rush is copper

Check out ep. 72 of The 5-Minute Investor Podcast, with analysis on copper stocks Freeport-McMoRan and Capstone Copper.

EU authorizes new COVID vaccine from Pfizer and BioNTech

The EU grants marketing authorization to Pfizer and BioNTech's COVID-19 vaccine targeting the new XFG variant.

PharmaTher evaluating 3D printing for personalized peptide medicines

PharmaTher is out to evaluate its GMP-ready 3D printing platform for producing personalized peptide medicines with customized doses.

Why biotech is outpacing the AI slump: 3 stocks to watch

The biotech sector is outperforming the broader market, shining a light on stocks best-positioned to address unmet patient needs.